Intended use:
RIDASCREEN® Anti-ADM Antibodies is an enzyme linked immunoassay intended for the quantitative determination of antibodies to adalimumab (ATA) in human serum and plasma.
Key features
- CE-marked versions of the ELISA tests of KU Leuven
- Highly specific antibodies
- Validated in clinical trials
- Validated on automated ELISA readers (e.g. DSX®)
Therapeutic Drug Monitoring
Adalimumab (ADM) is an human antibody that targets the pro-inflammatory cytokine TNF-alpha. The introduction of adalimumab has revolutionized the treatment of chronic inflammatory diseases like inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthritis. It has been shown that adalimumab can induce deep remission and improve the patient’s quality of life. Some patients do not respond to adalimumab therapy upon induction (primary non-responders), while others lose response over time (secondary non-responders).
Immunogenicity
Secondary loss of response is often due to the development of anti-adalimumab antibodies (ATA), because of the immunogenic character of the drug. ATA can develop in any patient undergoing adalimumab therapy and are primarily neutralizing the activity of adalimumab through immunocomplex formation. In addition, these immunocomplexes are rapidly cleared from the system. Analytically, they are responsible for subtherapeutic adalimumab concentrations. Therefore, in the case of very low trough concentrations of adalimumab (< 1 μg/ml), subsequent measurement of ATA may be helpful to determine the optimal treatment strategy.
Diagnostic Value
The diagnostic value of the RIDASCREEN® Anti-ADM Antibodies lies in its ability to stratify patients with subtherapeutic adalimumab concentrations (< 1 µg/ml) in patients who need dose intensification or a drug (class) switch. Patients with low adalimumab concentrations (< 1 µg/ml) and low ATA titers can benefit from adalimumab dose intensification, as shown in several studies. However, the ATA titer of patients with low ATA titers undergoing a dose intensified treatment regimen must be adequately monitored. Patients that have high ATA titers are preferably switched to another drug, both within class or out of class.
Single Components:
| Art. No. | G09044 |
|---|---|
| Test format | Microtiterplate with 96 wells (12 strips with 8 breakable wells each) |
| Incubation time | 2 h 45 min |
| Hide Order now button (Shop) | 1 |
Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.
